Wegovy and libido in women: what's really going on

The decision you're probably weighing

If you're already on Wegovy, or thinking about starting, and libido is on your mind, you're likely asking a specific version of a bigger question: will this medicine make things better or worse in that part of my life? It's a reasonable thing to want to know, and not enough is said about it. The research doesn't give a clean answer, because several forces act simultaneously, and they don't all point the same way.

Significant weight loss tends to raise testosterone and lower oestrogen dominance in women, which can sharpen desire. Sleep apnoea, which affects libido directly, often improves. Joint pain eases. Many women report feeling more comfortable in their bodies. These effects, which emerge over months rather than weeks, frequently outweigh the early-phase dip that some women describe.

The early-phase dip is real, though. Nausea and fatigue (documented in the NHS medicines information for semaglutide as among the most common side effects) tend to peak in the first two to four weeks at each new dose level. When you feel rough, sex is usually not high on the agenda. That doesn't mean your libido has changed; it means your body is adjusting. For most women, it passes.

So the decision framing here is: are you trying to establish whether a libido change is temporary, treatment-related, or something else entirely? The sections below help you think through each of those possibilities. You can also read more about how semaglutide affects women specifically, including the hormonal picture in more detail.

What the current evidence does and doesn't say

There is no large, well-controlled clinical trial specifically measuring semaglutide's effect on female libido. That gap in the evidence matters. What we do have comes from STEP 1 (the pivotal 68-week trial of 2.4mg semaglutide) which reported meaningful improvements in quality-of-life scores, including physical functioning, vitality and mental health. Women in the trial also reported lower rates of depression and better self-reported wellbeing at week 68 compared with placebo.

Better wellbeing and less depression are, for most women, associated with a more active interest in sex. So the indirect evidence tilts positive over the longer term. What the trial did not capture is granular data on sexual function week by week, particularly in the early titration period when GI side effects are at their highest.

There is a plausible biological mechanism worth knowing about. GLP-1 receptor agonists influence dopamine pathways in the brain involved in reward and motivation, pathways that also shape sexual desire. Whether this has a net positive or negative effect varies between individuals. For more on the mechanism and what women's experiences suggest, the question of whether semaglutide affects libido is explored in detail on a dedicated page.

The NHS England guidance on weight-management injections notes that hormonal changes associated with significant weight loss can affect contraceptive efficacy and reproductive hormone levels, a reminder that the body is being altered at a meaningful biological level, and sexual health sits within that picture.

When low libido on Wegovy is a signal worth investigating

If your sex drive dropped noticeably after starting Wegovy and hasn't recovered several months in (particularly if nausea has settled and you're losing weight steadily) it's worth investigating rather than assuming it's the medicine's fault.

Several things can look like a Wegovy side effect but have a different cause. Eating considerably less can reduce caloric intake below what's needed to sustain normal hormone production; protein deficiency in particular can lower testosterone. Iron deficiency, which becomes more common when appetite is significantly suppressed, is a known libido suppressant and is frequently overlooked. Women approaching perimenopause may find that weight loss uncovers or accelerates oestrogen changes that were previously masked.

Low mood that persists beyond the initial adjustment period is also worth naming. Some women find that losing weight quickly surfaces complicated feelings about their body, identity and relationships. That's not a medical diagnosis, it's an honest observation. If that resonates, it's worth talking to your prescriber and, separately, a counsellor if you want to.

You can read about the broader benefits semaglutide offers women (including its effects on polycystic ovary syndrome and cardiovascular risk) to get a fuller picture of what's changing in the body. If you have questions about how Wegovy can affect libido, including what the evidence suggests about desire over the course of treatment, that page sets out the picture in full. Women who are specifically concerned about experiencing low libido while taking Wegovy will find practical guidance on what to monitor and when to seek advice. If you have specific concerns about your current treatment, the contact page connects you with our aftercare team, available seven days a week.

Wegovy is a prescription-only medicine. Thinking about starting? A prescriber who reviews your full health picture (not a brief online form processed by software) is the right place to begin. If you'd like to understand the cost side of treatment first, the Wegovy pricing page sets out what's involved. When you're ready, starting your free consultation is the next step: our prescribers review consultations the same day, and many women find it useful to raise libido-related concerns directly in their initial assessment.